Congress returns from its summer recess with a long list of tasks and only a few work days to get them done. On top of the annual spending bills needed to keep the government operating, on the list are bills to renew the global HIV/AIDS program, PEPFAR, and the community health centers program. Meanwhile, over the recess, the Biden administration released the names of the first 10 drugs selected for the Medicare price negotiation program.
The proposal would require major hiring at the most sparsely-staffed homes. But the proposal is already badly received by the nursing home industry which claims it can’t boost wages enough to attract workers.
Research commissioned by the Centers for Medicare & Medicaid Services analyzed only staffing levels lower than the current federal standard. Patient advocates have been pushing for more staff to improve care.
The federal government is proposing having Medicare pay professionals to train family caregivers how to perform tasks like bathing and dressing their loved ones, and properly use medical equipment.
Clinics serving Alzheimer’s patients are working out the details of who will get treated with the new drug Leqembi. It won’t be for everyone with memory-loss symptoms.
The annual cost of lecanemab treatment quadruples if the expense of brain scans to monitor for bleeds and other associated care is factored in. The full financial toll likely puts it beyond reach for low-income seniors at risk of Alzheimer’s, experts say.
Although nearly 40% of Americans 60 and older are obese, Medicare doesn’t cover weight loss medications. Meanwhile, studies haven’t thoroughly examined new drugs’ impact on older adults.
Researchers have found that while obesity at any age risks harming health, a few extra pounds in later life isn’t cause for concern.
Black patients and other minorities tend to be diagnosed at later stages of the disease, which would exclude them from use of Leqembi. Few Black people were included in the main trial of the drug.
People with dementia and their families often find themselves with few legal rights when dealing with financial scams or the mismanagement of their assets. Research reveals financial troubles can be both an early sign and a painful symptom of cognitive decline.
